Immunosuppressive signaling pathways as targeted cancer therapies

dc.contributor.authorSetlai, Botle Precious
dc.contributor.authorHull, Rodney
dc.contributor.authorBida, Nndweleni Meshack
dc.contributor.authorDurandt, Chrisna
dc.contributor.authorMulaudzi, Thanyani Victor
dc.contributor.authorChatziioannou, Aristotelis
dc.contributor.authorDlamini, Zodwa
dc.contributor.emailprecious.setlai@up.ac.zaen_US
dc.date.accessioned2022-07-22T06:37:49Z
dc.date.available2022-07-22T06:37:49Z
dc.date.issued2022-03
dc.description.abstractImmune response has been shown to play an important role in defining patient prognosis and response to cancer treatment. Tumor-induced immunosuppression encouraged the recent development of new chemotherapeutic agents that assists in the augmentation of immune responses. Molecular mechanisms that tumors use to evade immunosurveillance are attributed to their ability to alter antigen processing/presentation pathways and the tumor microenvironment. Cancer cells take advantage of normal molecular and immunoregulatory machinery to survive and thrive. Cancer cells constantly adjust their genetic makeup using several mechanisms such as nucleotide excision repair as well as microsatellite and chromosomal instability, thus giving rise to new variants with reduced immunogenicity and the ability to continue to grow without restrictions. This review will focus on the central molecular signaling pathways involved in immunosuppressive cells and briefly discuss how cancer cells evade immunosurveillance by manipulating antigen processing cells and related proteins. Secondly, the review will discuss how these pathways can be utilized for the implementation of precision medicine and deciphering drug resistanceen_US
dc.description.departmentSurgeryen_US
dc.description.sponsorshipSouth African Medical Research Council (SAMRC) and National Research Foundation (NRF).en_US
dc.description.urihttp://www.mdpi.com/journal/biomedicinesen_US
dc.identifier.citationSetlai, B.P., Hull, R., Bida, M., Durandt, C., Mulaudzi, T.V., Chatziioannou, A. & Dlamini, Z. Immunosuppressive Signaling Pathways as Targeted Cancer Therapies. Biomedicines. 2022 Mar 16;10(3):682. doi: 10.3390/biomedicines10030682.en_US
dc.identifier.issn2227-9059 (online)
dc.identifier.other10.3390/biomedicines10030682
dc.identifier.urihttps://repository.up.ac.za/handle/2263/86384
dc.language.isoenen_US
dc.publisherMDPIen_US
dc.rights© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.en_US
dc.subjectPrecision medicineen_US
dc.subjectPI3K pathway inhibitorsen_US
dc.subjectCancer cellsen_US
dc.subjectImmune evasionen_US
dc.subjectImmunosuppressionen_US
dc.titleImmunosuppressive signaling pathways as targeted cancer therapiesen_US
dc.typeArticleen_US

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Setlai_Immunosuppressive_2022.pdf
Size:
3.09 MB
Format:
Adobe Portable Document Format
Description:
Article

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.75 KB
Format:
Item-specific license agreed upon to submission
Description: